{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:10:10Z","timestamp":1791861010369,"version":"4.3.4"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003083","name":"European Association of Urology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003083","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Open Science"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.euros.2026.01.016","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T20:08:46Z","timestamp":1770840526000},"page":"90-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Perioperative Immune Checkpoint Inhibitors Combined with Radical Cystectomy: A Rapid Systematic Review and Meta-analysis"],"prefix":"10.1016","volume":"85","author":[{"given":"Navid","family":"Roessler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Miszczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Miyajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Rajwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"von Deimling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malte W.","family":"Vetterlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"D\u2019Andrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margit","family":"Fisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euros.2026.01.016_b0005","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00345-006-0117-8","article-title":"Staged based directed surveillance of invasive bladder cancer following radical cystectomy: valuable and effective?","volume":"24","author":"Donat","year":"2006","journal-title":"World J Urol"},{"key":"10.1016\/j.euros.2026.01.016_b0010","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.juro.2008.03.024","article-title":"Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later","volume":"180","author":"Ghoneim","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2026.01.016_b0015","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2026.01.016_b0020","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.3390\/cancers14051222","article-title":"Effect of neoadjuvant chemotherapy on complications, in-hospital mortality, length of stay and total hospital costs in bladder cancer patients undergoing radical cystectomy","volume":"14","author":"Hoeh","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.euros.2026.01.016_b0025","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1007\/s00345-018-2584-0","article-title":"Impact of neoadjuvant chemotherapy on short-term complications and survival following radical cystectomy","volume":"37","author":"Milenkovic","year":"2019","journal-title":"World J Urol"},{"key":"10.1016\/j.euros.2026.01.016_b0030","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2026.01.016_b0035","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"10.1016\/j.euros.2026.01.016_b0040","doi-asserted-by":"crossref","first-page":"S1648","DOI":"10.1016\/j.annonc.2025.09.124","article-title":"LBA2 Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: the phase 3 KEYNOTE-905 study","volume":"36","author":"Vulsteke","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euros.2026.01.016_b0045","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JCO.24.00340","article-title":"Adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma: expanded efficacy from CheckMate 274","volume":"43","author":"Galsky","year":"2025","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.euros.2026.01.016_b0050","doi-asserted-by":"crossref","first-page":"S1482","DOI":"10.1016\/j.annonc.2025.08.3682","article-title":"3068O Adjuvant nivolumab vs placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274","volume":"36","author":"Galsky","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euros.2026.01.016_b0055","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","article-title":"Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Bellmunt","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euros.2026.01.016_b0060","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.eururo.2023.06.007","article-title":"Updated overall survival by circulating tumor DNA status from the phase 3 IMvigor010 trial: adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"85","author":"Powles","year":"2024","journal-title":"Eur Urol"},{"issue":"4 Suppl","key":"10.1016\/j.euros.2026.01.016_b0065","article-title":"AMBASSADOR Alliance A031501: phase III randomized adjuvant study of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma (MIUC) versus observation","volume":"42","author":"Apolo","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2026.01.016_b0070","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa2401726","article-title":"Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"392","author":"Apolo","year":"2025","journal-title":"N Engl J Med"},{"issue":"5 Suppl","key":"10.1016\/j.euros.2026.01.016_b0075","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1200\/JCO.2025.43.5_suppl.659","article-title":"Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA","volume":"43","author":"Galsky","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2026.01.016_b0080","doi-asserted-by":"crossref","unstructured":"Coca Membribes S, Powles T. Does adjuvant immune checkpoint inhibition therapy have a future in operable bladder cancer? Eur Urol Focus. In press. https:\/\/doi.org\/10.1016\/j.euf.2025.12.015.","DOI":"10.1016\/j.euf.2025.12.015"},{"issue":"Suppl 2","key":"10.1016\/j.euros.2026.01.016_b0085","doi-asserted-by":"crossref","first-page":"S1634","DOI":"10.1016\/j.annonc.2025.09.109","article-title":"LBA8 IMvigor011: a phase III trial of circulating tumour (ct)DNA-guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer","volume":"36","author":"Powles","year":"2025","journal-title":"Ann Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.euros.2026.01.016_b0090","doi-asserted-by":"crossref","first-page":"S1133","DOI":"10.1016\/j.annonc.2024.08.2045","article-title":"1960O Identification of bladder cancer patients that could benefit from early post-cystectomy immunotherapy based on serial circulating tumour DNA (ctDNA) testing: preliminary results from the TOMBOLA trial","volume":"35","author":"Bjerggaard Jensen","year":"2024","journal-title":"Ann Oncol"}],"container-title":["European Urology Open Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168326000303?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168326000303?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T17:02:50Z","timestamp":1773162170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666168326000303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":18,"alternative-id":["S2666168326000303"],"URL":"https:\/\/doi.org\/10.1016\/j.euros.2026.01.016","relation":{},"ISSN":["2666-1683"],"issn-type":[{"value":"2666-1683","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perioperative Immune Checkpoint Inhibitors Combined with Radical Cystectomy: A Rapid Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Urology Open Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euros.2026.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}